Fig. 7: PSGL-1 combination nanoparticle therapy decreased tumor burden, prolonged survival, and reduced adverse events in vivo. | Nature Communications

Fig. 7: PSGL-1 combination nanoparticle therapy decreased tumor burden, prolonged survival, and reduced adverse events in vivo.

From: Tumor microenvironment-targeted nanoparticles loaded with bortezomib and ROCK inhibitor improve efficacy in multiple myeloma

Fig. 7

a MM burden of mice treated with (i) free, (ii) non-targeted, and (iii) PSGL-1-targeted forms of treatment (vehicle, Y27632, BTZ, and Y27632 + BTZ) measured using bioluminescence. Data presented here are defined as mean values +/−SEM. b Survival of mice treated with (i) free, (ii) non-targeted, and (iii) PSGL-1-targeted drugs. c Percent weight change of mice in each group; each group was stratified by the form of treatment injected (all p values shown are <0.05; n = 3, n = 7, and n = 6 samples examined over one independent experiment for the groups: free, non-targeted, and PSGL-1-targeted, respectively). Data presented here are defined as mean values +/−SD. d Representative images of hair loss experienced in vivo following BTZ and combination treatments (free, non-targeted, and PSGL-1-targeted). For the experiments seen here, each mouse represents an independent replicate. Statistical significance was analyzed using an unpaired Student’s two-sided t-test (*p < 0.05).

Back to article page